Core Viewpoint - President Trump's comments regarding Tylenol's potential link to autism during pregnancy have created a significant crisis for Kenvue, potentially reviving litigation that the company had previously managed to dismiss [1][4]. Group 1: Legal Implications - The FDA is in the process of changing the labeling for acetaminophen products to indicate a higher risk of autism when used by pregnant women, which could lead to increased lawsuits against Kenvue [2][3]. - If the FDA's label change is implemented, it may provide plaintiffs with new evidence to support their claims against Kenvue regarding autism risks [3][6]. - Legal experts suggest that the new FDA warning could be influential in court, despite the lack of established causality between acetaminophen and autism [6]. Group 2: Company Challenges - Kenvue is currently facing a public relations crisis, reminiscent of past incidents, while also trying to revamp its business and address declining sales under interim CEO Kirk Perry [4]. - The renewed focus on potential autism risks could complicate Kenvue's efforts to maintain investor confidence and stabilize its operations [4][5]. - Historical context includes a significant legal defeat for Kenvue's former parent company, Johnson & Johnson, which may embolden current litigation efforts against Kenvue [5].